PRESENTATION
Q4 2024 — Presentation
Q4 2024PDF · 18 pages236 KB
Elevance Health 4Q 2024 Earnings Presentation January 23, 2025 -- 1 of 18 -- 22 The Value We Deliver We advance whole health through innovative solutions that integrate physical, behavioral, and social care to achieve our purpose of improving the health of humanity For Consumers Simple, Affordable, and Accessible Health Care 1. Simplifying healthcare through enhanced digital capabilities that personalize member experiences 2. Affordability at the core of our innovative plan designs 3. Accessibility through advocacy and data driven solutions that operationalize whole health 1. Differentiated clinical partnerships built on shared expertise and coordinated care 2. Advanced clinical collaboration and value-based care 3. Aligned business partner through digital tools that enhance information exchange and reduce administrative burden For Care Providers Deepen Clinical and Business Partnerships -- 2 of 18 -- 3 Key Highlights • Elevance Health fourth quarter results were consistent with guidance • 4Q 2024 and full year operating revenue of $45.0 and $175.2 billion, respectively • 4Q 2024 and full year medical loss ratio of 92.4% and 88.5%, respectively • 4Q 2024 and full year adjusted diluted EPS1 of $3.84 and $33.04, respectively 2024 Results 1 • 2025 adjusted diluted EPS1 in the range of $34.15 – $34.85 • Operating revenue expansion in the high single to low double digit percentage range reflects revenue acceleration across most major lines of business and the impact of recent acquisitions • Medical loss ratio projected to be 89.1% +/- 50 bps • Adjusted Operating gain1 projected to be in the range of $9.55 - $9.85 billion • Medical membership expected to end in the range of 45.8 – 46.6 million members 2025 Outlook 2 • Partnering with states to ensure rates accurately reflect higher Medicaid cost trends, building upon our positioning and performance in 2025 Medicare Advantage annual enrollment, and delivering innovative, affordable products in the Commercial market • Expanding Carelon capabilities to further drive our enterprise flywheel for growth • Investing to position Elevance Health for long-term, sustainable growth as we ensure the earnings power of our diverse and complementary businesses remains strong Strategic Focus Areas 3 1. See “GAAP Reconciliation” on slides 15 and 16 herein. -- 3 of 18 -- 44 Key Highlights • Elevance Health fourth quarter and full year results were consistent with guidance • Operating revenue of $175.2B in 2024 grew approximately 3% on improved premium yields in Health Benefits, acquisitions completed in 2024, and growth in CarelonRx product revenue, partly offset by Medicaid membership attrition • Medical loss ratio of 88.5% for the year, an increase of 150 bps, primarily reflects higher Medicaid cost trends • Adjusted operating expense ratio in 2024 of 10.6%, an improvement of 70 bps, reflects disciplined cost management and certain non- recurring expense benefits • Operating cash flow of $5.8B, or 1.0 times net income Fourth Quarter & Full Year 2024 Results Change (%/bps/$) 2023 2024 Change (%/bps) 4Q 2023 4Q 2024 Elevance Health 2.9% $170.2B $175.2B 6.0% $42.5B $45.0B Operating Revenue 1 150 bps 87.0% 88.5% 320 bps 89.2% 92.4% Medical Loss Ratio (70) bps 11.3% 10.6% (170) bps 11.6% 9.9% Adjusted Operating Expense Ratio1,2 (1.1%) $9.4B $9.3B (24.0%) $1.4B $1.0B Adjusted Operating Gain1,2 (20) bps 5.5% 5.3% (90) bps 3.2% 2.3% Adjusted Operating Margin 1,2 12.4% $1.8B $2.1B (0.4%) $529M $527M Net Investment Income (0.3%) $33.14 $33.04 (31.7%) $5.62 $3.84 Adjusted Diluted EPS 2 ($2.3B) $8.1B $5.8B $3.7B ($3.0B) $0.7B Operating Cash Flow 1. See “Basis of Presentation” on slide 14 herein. 2. See “GAAP Reconciliation” on slides 15 and 16 herein. -- 4 of 18 -- 55 2024 Actual 2025 Outlook Elevance Health $144.2B Low Double Digit Growth Premium Revenue $22.6B Low Single Digit Growth Product Revenue $8.4B Approximately Flat Service Fees $175.2B High Single to Low Double Digit Growth Total Operating Revenue1 88.5% 89.1% +/- 50 bps Medical Loss Ratio 10.6% 10.4% +/- 50 bps Adjusted Operating Expense Ratio 1,2 $9.3B $9.55 – $9.85B Adjusted Operating Gain 1,2 $2.05B ~$1.88B Net Investment Income $1.19B ~$1.48B Interest Expense $33.04 $34.15 – $34.85 Adjusted Diluted EPS 2 $5.8B Approximately $8.0B Operating Cash Flow 2025 Outlook Key Highlights • 2025 full year guidance for adjusted diluted earnings per share in the range of $34.15 – $34.85 • Operating revenue outlook reflects the impact of higher premium yields and recent acquisitions • Medical loss ratio expected to be up 60 bps at the midpoint; medical cost trend expected to be elevated but stable; mix headwind from recent acquisitions • Adjusted operating expense ratio to be 20 bps below 2024 levels at the midpoint due to ongoing operating efficiencies and targeted expense actions • Net investment income declines on lower cash balances and rate outlook; interest expense increases following recent acquisitions 1. See “Basis of Presentation” on slide 14 herein. 2. See “GAAP Reconciliation” on slides 15 and 16 herein. -- 5 of 18 -- 66 Key Highlights • Health Benefits results reflect navigation of a dynamic operating environment due to Medicaid cost pressure, partly offset by strong performance in Commercial • Operating revenue grew 2.8% year over year in the fourth quarter driven by higher premium yields, offset by declines in Medicaid membership • Adjusted operating margin was impacted by higher cost trend in Medicaid related to redeterminations • Guidance for operating revenue growth reflects slight membership gains and rate improvement • Operating margin expectations reflect mix impacts, a prudent view of Medicaid cost trend, and lapping non-recurring expense benefits Change (%/bps) 2023 2024 Change (%/bps) 4Q 2023 4Q 2024 Health Benefits 1.1% $148.6B $150.3B 2.8% $36.5B $37.6B Operating Revenue 1 (8.4%) $6.9B $6.3B (64.4%) $767M $273M Adjusted Operating Gain1,2 (40) bps 4.6% 4.2% (140) bps 2.1% 0.7% Adjusted Operating Margin 1,2 (2.3%) 46.8M 45.7M Membership 3 1. See “Basis of Presentation” on slide 14 herein. 2. See “Reportable Segment Highlight Details” on slide 17 herein. 3. Health Benefits Membership for the three months ended December 31, 2023, is restated to reflect a change in BlueCard® membership to align to the Blue Cross Blue Shield Association reporting methodology. For the three months ended December 31, 2023, BlueCard® membership has been restated lower by 132K. 2025 Outlook Guidance High Single Digit Operating Revenue Growth (50) – (25) basis points over 2024 GAAP Operating Margin 45.8M – 46.6M Membership Health Benefits 2024 Results | 2025 Outlook -- 6 of 18 -- 77 Key Highlights • Substantial progress in scaling our enterprise flywheel for growth; in the fourth quarter, we closed on the acquisitions of Kroger Specialty Pharmacy and CareBridge, further broadening the solutions offered to clients • CarelonRx fourth quarter operating revenue includes the impact of recent acquisitions and strong external member growth; 2025 operating margin remains within our target range of 6.0% – 6.5% • Carelon Services operating revenue expansion in 4Q 2024 driven by the launch and growth of risk-based products and recent acquisitions; 2025 operating margin includes dilutive impacts of the CareBridge acquisition and scaling our risk- based capabilities 2024 Results | 2025 Outlook Change (%/bps) 2023 2024 Change (%/bps) 4Q 2023 4Q 2024 Carelon 12.4% $48.0B $53.9B 18.9% $12.4B $14.7B Operating Revenue 1 16.9% $2.7B $3.1B 32.3% $592M $783M Adjusted Operating Gain1,2 30 bps 5.5% 5.8% 50 bps 4.8% 5.3% Adjusted Operating Margin 1,2 3.2% 308.4M 318.4M 6.3% 78.0M 82.9M Adjusted Scripts (2.1%) 103.3M 101.1M Consumers Served 1. See “Basis of Presentation” on slide 14 herein. 2. See “Reportable Segment Highlight Details” on slide 17 herein. 2025 Outlook Guidance Greater than 50% Carelon Services Operating Revenue Growth (100) – (50) basis points over 2024 Carelon Services GAAP Operating Margin Mid Teens CarelonRx Operating Revenue Growth 0 – 20 basis points over 2024 CarelonRx GAAP Operating Margin Health Services -- 7 of 18 -- 88 Flywheel Supports Our Long-Term Growth Algorithm Health Benefits Optimize the Core Invest in Growth Accelerate Targeting at least 12% average annual growth in Adjusted Diluted Earnings Per Share Approximately 46M medical members balanced across commercial, Medicaid and Medicare, leveraging the assets and capabilities of Carelon to accelerate growth Integrated portfolio of whole health solutions connecting care across physical, behavioral, social, home health, and pharmacy needs to bend the cost curve, enhance consumer experiences, and deliver whole health, affordably Health Services -- 8 of 18 -- 99 Adjusted Operating Gain – High Single Digit to Low Double Digit CAGR1 Long-Term Growth Algorithm Revenue Growth High Single Digit CAGR1 Adjusted Operating Margin Expanding to 6.5% - 7.0% Capital Deployment Approximately 4% Contribution to Adjusted Diluted EPS CAGR 1 Health Benefits Mid to High Single Digit CAGR Driven by membership growth, cost trend, geographic expansion, and growth in specialized populations Carelon Services High Teens to Low Twenties CAGR Driven by risk-based revenue growth including M&A CarelonRx Low Double Digit CAGR Driven by script volumes and drug mix Transforming our business processes by leveraging new technologies across operations Commitment to operating efficiency and optimizing core businesses Effective medical management Underwriting discipline Share Repurchases Organic Reinvestment Programmatic M&A targeting integrated solutions that strengthen health plan competitiveness + + Targeting at least 12% average annual growth in Adjusted Diluted EPS 1. CAGR = Compound Annual Growth Rate Target. -- 9 of 18 -- 10 10 Committed to Strong Growth Over the Long-Term M&A/ Organic Reinvestment 50% Share Repurchase 30% Dividends 20% 5.3% 6.5% – 7.0% 2024 Target $175B High Single Digit CAGR1 2024 Target Elevance Health 5.8% Mid to High Single Digit 2024 Target $54B Mid Teens CAGR1 2024 Target Carelon 2 4.2% 5.5% – 6.5% 2024 Target $150B Mid to High Single Digit CAGR1 2024 Target Health Benefits Capital Allocation Targeting at least 12% average annual growth in Adjusted Diluted EPS Adjusted 3 Operating Margin Revenue (in billions) 1. CAGR = Compound Annual Growth Rate Target. 2. The CAGR target for revenue and the operating margin target for Carelon includes: (i) a low double-digit revenue CAGR and 6.0% – 6.5% operating margin target for CarelonRx, and (ii) a high teens to low twenties revenue CAGR and mid to high single digit operating margin for Carelon Services. 3. See “GAAP Reconciliation” on slides 15 and 16 herein. -- 10 of 18 -- 11 11 The Value We Deliver for Consumers Simple, Affordable, and Accessible Health Care • More than a third of member interactions are facilitated through ‘live-chat’ functions, ensuring real time solutions to customer needs • Investing in our Sydney Health app to personalize the health experience and proactively answer member inquiries Simplifying healthcare through enhanced digital capabilities that personalize member experiences1 • Over 90% of our MA plans have no monthly premium in 2025; nearly all plans offer $0 copays for primary care visits and at least one supplemental benefit • Use of MA supplemental benefits was associated with a decreased likelihood of an inpatient admission and increased likelihood of an annual wellness visit or preventative screening • Care Transition Interventions (CTI) program led to a 14% decrease in costs for participants • Complex Care Management for Medicaid members reduced inpatient admissions by 7% Affordability at the core of our innovative plan designs 2 • Targeted digital interventions in 2024 saved members an estimated 1.5 million hours by enabling access to care, such as selecting a PCP or understanding a benefit • One in five members have closed a critical care gap through our digital channels, such as scheduling mammograms or colonoscopies Accessibility through advocacy and data driven solutions that operationalize whole health3 -- 11 of 18 -- 12 12 The Value We Deliver for Care Providers Deepen Clinical and Business Partnerships • Carelon Oncology Total Cost of Care program helped to resolve adverse events for oncology patients in lower cost settings • 60% of members enrolled in our Concierge Care program experienced fewer chemotherapy side-effect related admissions Differentiated clinical partnerships built on shared expertise and coordinated care 1 • Pay for nearly two thirds of care through value-based arrangements across all lines of business, with over 35% of payments to providers taking downside risk, up from 16% in 2021 • Managed nearly one million consumers through Mosaic Health across 19 states with 1,500+ providers, including 35% of lives at risk • Carelon Advanced Primary Care and Millennium Physician Group achieved NPS scores of 90 Advanced clinical collaboration and value-based care 2 • We partnered with a New York based health system to nearly eliminate claims denied for incomplete or incorrect information and are scaling this solution to other care providers • 89% of Medicare Advantage providers are connected to HealthOS, up from only 16% in 2021 Aligned business partner through digital tools that enhance information exchange and reduce administrative burden3 -- 12 of 18 -- 13 Forward-Looking Statements This document contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect our views about future events and financial performance and are generally not historical facts. Words such as “expect,” “feel,” “believe,” “will,” “may,” “should,” “anticipate,” “intend,” “estimate,” “project,” “forecast,” “plan” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to: financial projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond our control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. You are also urged to carefully review and consider the various risks and other disclosures discussed in our reports filed with the U.S. Securities and Exchange Commission from time to time, which attempt to advise interested parties of the factors that affect our business. Except to the extent required by law, we do not update or revise any forward-looking statements to reflect events or circumstances occurring after the date hereof. These risks and uncertainties include, but are not limited to: trends in healthcare costs and utilization rates; reduced enrollment; our ability to secure and implement sufficient premium rates; the impact of large scale medical emergencies, such as public health epidemics and pandemics, and other catastrophes; the impact of new or changes in existing federal, state and international laws or regulations, including laws and regulations impacting healthcare, insurance, pharmacy services and other diversified products and services, or their enforcement or application; the impact of cyber-attacks or other privacy or data security incidents or our failure to comply with any privacy, data or security laws or regulations, including any investigations, claims or litigation related thereto; failure to effectively maintain and modernize our information systems, or failure of our information systems or technology, including artificial intelligence, to operate as intended; failure to effectively maintain the availability and integrity of our data; changes in economic and market conditions, as well as regulations that may negatively affect our liquidity and investment portfolios; competitive pressures and our ability to adapt to changes in the industry and develop and implement strategic growth opportunities; risks and uncertainties regarding Medicare and Medicaid programs, including those related to non-compliance with the complex regulations imposed thereon; our ability to maintain and achieve improvement in Centers for Medicare and Medicaid Services Star Ratings and other quality scores and funding risks with respect to revenue received from participation therein; a negative change in our healthcare product mix; costs and other liabilities associated with litigation, government investigations, audits or reviews; our ability to contract with providers on cost-effective and competitive terms; risks associated with providing healthcare, pharmacy and other diversified products and services, including medical malpractice or professional liability claims and non-compliance by any party with the pharmacy services agreement between us and CaremarkPCS Health, L.L.C.; the effects of any negative publicity related to the health benefits industry in general or us in particular; risks associated with mergers, acquisitions, joint ventures and strategic alliances; possible impairment of the value of our intangible assets if future results do not adequately support goodwill and other intangible assets; possible restrictions in the payment of dividends from our subsidiaries and increases in required minimum levels of capital; our ability to repurchase shares of our common stock and pay dividends on our common stock due to the adequacy of our cash flow and earnings and other considerations; the potential negative effect from our substantial amount of outstanding indebtedness and the risk that increased interest rates or market volatility could impact our access to or further increase the cost of financing; a downgrade in our financial strength ratings; events that may negatively affect our licenses with the Blue Cross and Blue Shield Association; intense competition to attract and retain employees; risks associated with our international operations; and various laws and provisions in our governing documents that may prevent or discourage takeovers and business combinations. -- 13 of 18 -- 14 Non-GAAP Measures and Basis of Presentation This document references non-GAAP measures. These non-GAAP measures are intended to aid investors when comparing Elevance Health’s financial results among periods and are not intended to be alternatives to any measure calculated in accordance with GAAP. Reconciliations of these non-GAAP measures to the most directly comparable measures calculated in accordance with GAAP are available on the last slide of this document. Operating revenue and operating gain/loss are the key measures used by management to evaluate performance in each of its reporting segments, allocate resources, set incentive compensation targets and to forecast future operating performance. Operating gain/loss is calculated as total operating revenue less benefit expense, cost of products sold and operating expense. It does not include net investment income, net gains/losses on financial instruments, interest expense, amortization of other intangible assets and gains/losses on extinguishment of debt or income taxes, as these items are managed in a corporate shared service environment and are not the responsibility of operating segment management. Operating Margin is defined as operating gain divided by operating revenue. Each of these measures is provided to further aid investors in understanding and analyzing Elevance Health’s operating and financial results. -- 14 of 18 -- 15 15 Elevance Health GAAP Reconciliation — Shareholders’ Net Income and Shareholders’ Earnings Per Diluted Share Twelve Months Ended Dec 31 Three Months Ended Dec 31 Change 2023 2024 Change 2023 2024 (In millions, except per share data) (0.1)% $5,987 $5,980 (51.2)% $856 $418 Shareholders' net income Add / (Subtract): — 281 — 281 Business dispositions and related items 1 885 580 217 180 Amortization of other intangible assets 694 445 336 74 Net losses on financial instruments 213 224 59 66 Transaction and integration related costs2 (2) 692 (7) 12 Litigation and settlement expenses2 — (201) — — Gain on sale of business 719 268 22 — Business optimization charges 2 (628) (575) (158) (143) Tax impact of non-GAAP adjustments 1,881 1,714 469 470 Net adjustment items (2.2)% $7,868 $7,694 (33.0)% $1,325 $888 Adjusted shareholders' net income 1.8% $25.22 $25.68 (50.1)% $3.63 $1.81 Shareholders’ earnings per diluted share Add / (Subtract): — 1.21 — 1.22 Business dispositions and related items 1 3.73 2.49 0.92 0.78 Amortization of other intangible assets 2.92 1.91 1.42 0.32 Net losses on financial instruments 0.90 0.96 0.25 0.29 Transaction and integration related costs2 (0.01) 2.97 (0.03) 0.05 Litigation and settlement expenses2 — (0.86) — — Gain on sale of business 3.03 1.15 0.09 — Business optimization charges 2 (2.65) (2.47) (0.67) (0.62) Tax impact of non-GAAP adjustments 7.92 7.36 1.99 2.03 Net adjustment items (0.3)% $33.14 $33.04 (31.7)% $5.62 $3.84 Adjusted shareholders’ earnings per diluted share Twelve Months Ended Dec 31 Three Months Ended Dec 31 Change 2023 2024 Change 2023 2024 (In millions) 2.4% $7,715 $7,904 (39.5)% $1,001 $606 Income before income tax expense (1,825) (2,051) (529) (527) Net investment income — (201) — — Gain on sale of business 694 445 336 74 Net losses on financial instruments 1,030 1,185 259 340 Interest expense 885 580 217 180 Amortization of other intangible assets (7.5)% $8,499 $7,862 (47.6)% $1,284 $673 Reportable segments operating gain 1. Adjustment item resides in the Health Benefits and Carelon Services reportable segments. 2. Adjustment item resides in the Corporate & Other reportable segment. 3. Totals may not foot due to rounding. -- 15 of 18 -- 16 16 Elevance Health GAAP Reconciliation — Operating Gain, Operating Expense Ratio, and 2025 Outlook Twelve Months Ended Dec 31 Three Months Ended Dec 31 Change 2023 2024 Change 2023 2024 (In millions) (0.3)% $20,087 $20,025 (3.9)% $4,999 $4,804 Operating expense Add / (Subtract): — (281) — (281) Business dispositions and related items 1 (213) (224) (59) (66) Transaction and integration related costs2 2 (692) 7 (12) Litigation and settlement expenses2 (719) (268) (22) — Business optimization charges 2 (930) (1,465) (74) (359) Net adjustment items (3.1)% $19,157 $18,560 (9.7)% $4,925 $4,445 Adjusted operating expense 2.9% $170,209 $175,204 6.0% $42,454 $44,989 Operating revenue (40) bp 11.8% 11.4% (110) bp 11.8% 10.7% Operating expense ratio (70) bp 11.3% 10.6% (170) bp 11.6% 9.9% Adjusted operating expense ratio Twelve Months Ended Dec 31 Three Months Ended Dec 31 Change 2023 2024 Change 2023 2024 (In millions) (7.5)% $8,499 $7,862 (47.6)% $1,284 $673 Reportable segments operating gain Add / (Subtract): — 281 — 281 Business dispositions and related items 1 213 224 59 66 Transaction and integration related costs2 (2) 692 (7) 12 Litigation and settlement expenses2 719 268 22 — Business optimization charges 2 930 1,465 74 359 Net adjustment Items (1.1)% $9,429 $9,327 (24.0)% $1,358 $1,032 Reportable segments adjusted operating gain Full Year 2025 Outlook $30.40 to $31.10 Shareholders’ earnings per diluted share Add / (Subtract): $2.57 Amortization of other intangibles 3 $1.12 Net losses on financial instruments3 $1.11 Transaction and integration related costs2, 3 $0.04 Litigation and settlement expenses2, 3 Approximately ($1.09) Tax impact of non-GAAP adjustments3 $3.75 Net adjustment items $34.15 to $34.85 Adjusted shareholders’ earnings per diluted share 1. Adjustment item resides in the Health Benefits and Carelon Services reportable segments. 2. Adjustment item resides in the Corporate & Other reportable segment. 3. Adjustment item represents the midpoint of a projected range and serves as the estimated full year adjustment amount. -- 16 of 18 -- 17 17 Elevance Health Reportable Segment Highlight Details Twelve Months Ended Dec 31 Three Months Ended Dec 31 Change 2023 2024 Change 2023 2024 (In millions, Unaudited) Operating Revenue 1.1% $148,571 $150,275 2.8% $36,547 $37,580 Health Benefits 6.3% 33,835 35,961 13.0% 8,827 9,977 CarelonRx 27.0% 14,147 17,961 33.4% 3,574 4,769 Carelon Services (35.5)% 479 309 NM 5 181 (14) Corporate & Other 9.2% (26,823) (29,302) 9.7% (6,675) (7,323) Eliminations 2.9% $170,209 $175,204 6.0% $42,454 $44,989 Total Operating Revenue1 Operating Gain (Loss) (9.4)% $6,888 $6,243 (73.0)% $767 $207 Health Benefits 2 10.0% 1,975 2,172 8.8% 490 533 CarelonRx 5.4% 680 717 (65.7)% 102 35 Carelon Services2 NM 5 (1,044) (1,270) NM 5 (75) (102) Corporate & Other 2,3 (7.5)% $8,499 $7,862 (47.6)% $1,284 $673 Total Operating Gain1,4 Operating Margin (40) bp 4.6% 4.2% (150) bp 2.1% 0.6% Health Benefits 20 bp 5.8% 6.0% (30) bp 5.6% 5.3% CarelonRx (80) bp 4.8% 4.0% (220) bp 2.9% 0.7% Carelon Services (50) bp 5.0% 4.5% (150) bp 3.0% 1.5% Total Operating Margin1 1. See “Basis of Presentation” on page 14 herein. 2. Operating gain for the three and twelve months ended December 31, 2024 included $281 of business dispositions and related items excluded from adjusted shareholders' net income; including $215 for the Carelon Services segment; and $66 for the Health Benefits segment. Operating gain for the three and twelve months ended December 31, 2024 included $66 and $224, respectively, of transaction and integration related costs, all of which resides in the Corporate & Other reportable segment. Operating gain for the three and twelve months ended December 31, 2024 included $12 and $692, respectively, of litigation and settlement expenses, all of which resides in the Corporate & Other reportable segment. Operating gain for the twelve months ended December 31, 2024 included $268 of business optimization charges which reside in the Corporate & Other reportable segment. 3. Operating gain for the three and twelve months ended December 31, 2023 included; $59 and $213, respectively, of transaction and integration related costs; $22 and $719, respectively, of business optimization charges; and ($7) and ($2), respectively, of litigation and settlement expenses. 4. Operating Gain for the three and twelve months ended December 31, 2024, and December 31, 2023, included items excluded from adjusted shareholders' net income. See "GAAP Reconciliation" on slides 15 and 16 herein. 5. "NM" = calculation not meaningful. Elevance Health has four reportable segments: Health Benefits (comprised of Individual, Employer Group risk-based, Employer Group fee-based, BlueCard®, Medicare, Medicaid, and Federal Employee Program businesses); CarelonRx; Carelon Services; and Corporate & Other (comprised of businesses that do not individually meet the quantitative thresholds for an operating division as well as corporate expenses not allocated to our other reportable segments). -- 17 of 18 -- -- 18 of 18 --